DCP Capital invests over $283m in Shanghai-listed insulin maker

DCP Capital invests over $283m in Shanghai-listed insulin maker

Insulin Level Test Conducted by an EMT. Source: Matt Chesin/Unsplash

Eudora Wang

12 September, 2020

DCP Capitaldiabetesrecombinant human insulinTonghua Dongbao

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter

You may also like

Read more from Greater China

Nikkei Logo
DealStreetAsia Logo
About Us
Team
Advertise
Contact
Careers
Blog
Privacy Policy
Terms & Conditions
© Copyright DEALSTREETASIA 2014-2025 All rights reserved.